Botswana is poised to introduce a new injectable HIV prevention drug that could reshape how people protect themselves against infection particularly those who struggle with daily medication.
Lenacapavir, a long-acting injection taken twice a year, is being rolled out globally with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States.
Botswana is among 12 new countries set to benefit from the next phase of expansion, as global health agencies aim to reach three million people with the drug by 2028.
Advocates say the injection offers a more private and convenient alternative to daily pills, which many users discontinue due to stigma or forgetfulness.
In countries where rollout has already begun – including Lesotho and Eswatini – early signs show strong demand, especially among young women and first-time users of HIV prevention services.
Advocates say the injection offers a more private and convenient alternative to daily pills, which many users discontinue due to stigma or forgetfulness.
The UNAIDS has described the rollout as a critical step forward but stressed that affordability and equitable access remain major concerns.
For Botswana, where HIV continues to disproportionately affect young women, the new intervention is expected to strengthen prevention efforts and close persistent gaps in access.
It is understood that health authorities are now expected to map out how the drug will be introduced nationwide including which populations will be prioritised.
